Skyhawk Therapeutics has announced that its investigational drug, SKY-0515, has met the eligibility criteria for provisional registration by Australia’s Therapeutic Goods Administration (TGA). This decision marks a significant step forward in the treatment of Huntington’s disease, a progressive and debilitating neurodegenerative disorder.
The TGA’s provisional approval pathway allows for expedited access to promising therapies while additional data is collected. Skyhawk submitted its application for this provisional approval on March 3, 2026. Currently, over 115 patients are participating in the trial for SKY-0515, which is an orally administered small molecule therapy designed to target and modulate RNA to potentially slow the progression of Huntington’s disease.
Bill Haney, CEO of Skyhawk Therapeutics, expressed gratitude for the TGA’s decision, stating, “This represents an important first step toward what could be an accelerated path to approval in Australia and the world.” He emphasized the need for effective treatments for patients suffering from this devastating condition.
Clinical trials of SKY-0515 have shown promising results in reducing levels of mutant huntingtin protein (mHTT) and PMS1, both of which are implicated in the pathology of Huntington’s disease. In the ongoing Phase 1C trial, patients receiving the treatment demonstrated a mean improvement of +0.64 points on the Composite Unified Huntington’s Disease Rating Scale (cUHDRS) after nine months, contrasting with an expected decline of -0.73 points in symptomatic individuals.
Huntington’s disease affects hundreds of thousands globally, with more than 40,000 symptomatic patients in the United States and over 2,000 Australians. Currently, there are no approved disease-modifying treatments available to slow or halt the progression of this hereditary disorder.
Details of Clinical Trials
SKY-0515’s Phase 1 clinical study is structured into three parts. Parts A and B focused on assessing the drug’s safety and tolerability in healthy volunteers, while Part C involves a double-blind, placebo-controlled study targeting individuals with early stages of Huntington’s disease. The trial runs for 84 days, followed by a 12-month extension during which all participants will receive active treatment.
The objectives of the study include measuring the effects of SKY-0515 on mutant HTT protein and PMS1 mRNA levels. The first patients in Part C were dosed in January 2025, and enrollment for this phase is now complete.
In addition to the Phase 1 trial, Skyhawk is advancing toward a Phase 2/3 study, known as FALCON-HD. This randomized, double-blind, placebo-controlled trial will evaluate the safety and efficacy of SKY-0515 across 12 sites in Australia and New Zealand, with a total of 120 participants expected to be enrolled. The study aims to confirm the drug’s ability to modulate RNA splicing and its potential impact on slowing disease progression.
The FALCON-HD trial will involve participants receiving a once-daily oral dose of SKY-0515 at one of three dose levels or a placebo, over a treatment period of at least 12 months. Further details about the trial, including eligibility criteria, can be found on ClinicalTrials.gov.
About Skyhawk Therapeutics
Skyhawk Therapeutics is a clinical-stage biotechnology firm focused on developing innovative small molecule therapies utilizing its proprietary SKYSTAR® platform. This platform allows for the discovery of RNA-modulating treatments for challenging neurological disorders.
For more information about Skyhawk Therapeutics and its ongoing research, visit their website at www.skyhawktx.com.
This advancement in the treatment landscape for Huntington’s disease represents hope for patients and families affected by this serious condition.
